PET/CT as a Surrogate for Monitoring Treatment Outcomes in Sarcoidosis
Clinical Nuclear Medicine Open · 2026-06 · 3 (2)
DOI: 10.1097/nm9.0000000000000072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nuclear Medicine Open, 2026-06. Verfasst von Berkay Dincer und 3 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Sarcoidosis is a multisystem granulomatous disease with no single reliable marker to monitor treatment response. FDG-PET/CT enables visualization of active inflammation and differentiation from irreversible fibrotic disease. We conducted a narrative review and a case series of ten pulmonary sarcoidosis patients followed at an academic tertiary-care center, comparing baseline and 1-year PET/CT findings with clinical status and treatment changes. After 1 year, 5 patients demonstrated clinical improvement with medication reduction, accompanied by decreased lesion burden and SUV on PET/CT, including complete resolution in several cases. Biomarkers did not consistently correlate with imaging findings. These results support FDG-PET/CT as a valuable adjunct for assessing treatment response when conventional markers are inconclusive.
Zitieren
APA
Dincer, B., Khakoo, N., Safayeth, I. J., & Mirsaeidi, M. (2026). PET/CT as a Surrogate for Monitoring Treatment Outcomes in Sarcoidosis. Clinical Nuclear Medicine Open, 3(2). https://doi.org/10.1097/nm9.0000000000000072
Vancouver
Dincer B, Khakoo N, Safayeth IJ, Mirsaeidi M. PET/CT as a Surrogate for Monitoring Treatment Outcomes in Sarcoidosis. Clinical Nuclear Medicine Open. 2026;3(2). doi:10.1097/nm9.0000000000000072
BibTeX
@article{Dincer2026,
author = {Dincer, Berkay and Khakoo, Nidah and Safayeth, Isma Jabeen and Mirsaeidi, Mehdi},
title = {PET/CT as a Surrogate for Monitoring Treatment Outcomes in Sarcoidosis},
journal = {Clinical Nuclear Medicine Open},
year = {2026},
volume = {3},
number = {2},
doi = {10.1097/nm9.0000000000000072}
}
EUVIMED